perinatal hypoxic-ischemic brain injury | sciencenewsnet.in

Breaking News

Interplay between mesenchymal stem cells and macrophages: Promoting bone tissue repair

Biological scaffold as potential platforms for stem cells: Current development and applications in wound healing

Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19

Effects of high glucose and severe hypoxia on the biological behavior of mesenchymal stem cells at various passages

Gossypol acetic acid regulates leukemia stem cells by degrading LRPPRC via inhibiting IL-6/JAK1/STAT3 signaling or resulting mitochondrial dysfunction

Expansion of human umbilical cord derived mesenchymal stem cells in regenerative medicine

Unveiling the role of hypoxia-inducible factor 2alpha in osteoporosis: Implications for bone health

Reveal more mechanisms of precondition mesenchymal stem cells inhibiting inflammation

Adipose-derived regenerative therapies for the treatment of knee osteoarthritis

Barcodes expand range of high-resolution sensor

26 Apr, 2024

Scientists show MRI predicts the efficacy of a stem cell therapy for brain injury

May 12, 2020 sarah JonasResearch Results

Scientists at Sanford Burnham Prebys Medical Discovery Institute and Loma Linda University Health have demonstrated the promise of applying magnetic resonance imaging (MRI) to predict the efficacy of using human neural stem cells to treat a brain injury—a first-ever “biomarker” for regenerative medicine that could help personalize stem cell treatments for neurological disorders and improve efficacy. The study was published in Cell Reports.

$4.96 million CIRM grant awarded to Sanford Burnham Prebys to help the tiniest patients

August 19, 2019 sarah JonasAnnouncement

The California Institute for Regenerative Medicine (CIRM) has awarded a $4.96 million grant to Sanford Burnham Prebys Professor Evan Y. Snyder, M.D., Ph.D. The funding will allow Snyder to complete pre-investigational new drug (IND)-enabling studies, a step toward securing U.S. Food & Drug Administration (FDA) approval of a human trial for neural stem cells as a potential treatment for newborns who experience oxygen and blood-flow deprivation during birth. Called perinatal hypoxic-ischemic brain injury (HII), the lack of oxygen and blood flow to the brain can cause cerebral palsy and other permanent neurological disorders.